[Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction

Biomaterials

Volumn 37, Issue , 2015, Pages 289-298

  Serpooshan, Vahid ^a,b   Sivanesan, Senthilkumar ^b   Huang, Xiaoran ^b   Mahmoudi, Morteza ^a,b   Malkovskiy, Andrey V ^b   Zhao, Mingming ^a   Inayathullah, Mohammed ^b   Wagh, Dhananjay ^b   Zhang, Xuexiang J ^b   Metzler, Scott ^a   Bernstein, Daniel ^a,b   Wu, Joseph C ^b   Ruiz Lozano, Pilar ^a,b   Rajadas, Jayakumar ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertrophy; Liposomal encapsulation; Nanocarrier; Sustained release; TAC; Pyr1 Apelin 13

Indexed keywords

ATOMIC FORCE MICROSCOPY; BIOCHEMISTRY; CARDIOLOGY; CONJUGATED POLYMERS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; HEART; LIGHT SCATTERING; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PATHOLOGY;

DEVELOPMENT AND APPLICATIONS; HYPERTROPHY; INTRAPERITONEAL INJECTIONS; LIPOSOMAL NANOCARRIERS; LIPOSOMAL NANOPARTICLES; NANOCARRIERS; SUSTAINED RELEASE; [PYR1]-APELIN-13;

TARGETED DRUG DELIVERY;

APELIN; MACROGOL; NANOPARTICLE; UNCLASSIFIED DRUG; [PYR1]APELIN 13; APELIN-13 PEPTIDE; DRUG CARRIER; LIPOSOME; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD FLOW; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENCAPSULATION; HEART FAILURE; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART; LIGHT; PARTICLE SIZE; PATHOPHYSIOLOGY; PRESSURE; RADIATION SCATTERING; ULTRASTRUCTURE;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROCARDIOGRAPHY; HEART; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGHT; LIPOSOMES; MICE; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PARTICLE SIZE; PRESSURE; SCATTERING, RADIATION;

EID: 84922278202     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.045     Document Type: Article

References (82)

1. Frey N., Katus H.A., Olson E.N., Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 2004, 109:1580-1589.
2. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
3. Yoshida H., Imataki K., Nagahana H., Ihoriya F., Nakao Y., Saito D., et al. Cardiac hypertrophy in hypertrophic cardiomyopathy and hypertension evaluated by echocardiography and body surface isopotential mapping. JCardiogr 1986, 16:399-406.
4. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. NEngl J Med 1990, 322:1561-1566.
5. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345-352.
6. Olson E.N. Adecade of discoveries in cardiac biology. Nat Med 2004, 10:467-474.
7. Iemitsu M., Miyauchi T., Maeda S., Sakai S., Kobayashi T., Fujii N., et al. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 2001, 281:R2029-R2036.
8. deAlmeida A.C., van Oort R.J., Wehrens X.H.T. Transverse aortic constriction in mice. JVis Exp JoVE 2010, 38:1729-1731.
9. Van Nierop B.J., van Assen H.C., van Deel E.D., Niesen L.B.P., Duncker D.J., Strijkers G.J., et al. Phenotyping of left and right ventricular function in mouse models of compensated hypertrophy and heart failure with cardiac MRI. PLoS ONE 2013, 8:e55424.
10. Patten R.D., Hall-Porter M.R. Small animal models of heart failure development of novel therapies, past and present. Circ Heart Fail 2009, 2:138-144.
11. Rockman H.A., Ross R.S., Harris A.N., Knowlton K.U., Steinhelper M.E., Field L.J., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an invivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 1991, 88:8277-8281.
12. Liao Y., Ishikura F., Beppu S., Asakura M., Takashima S., Asanuma H., et al. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol 2002, 282:H1703-H1708.
13. Nakamura A., Rokosh D.G., Paccanaro M., Yee R.R., Simpson P.C., Grossman W., et al. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 2001, 281:H1104-H1112.
14. Koguchi W., Kobayashi N., Takeshima H., Ishikawa M., Sugiyama F., Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J Off J Jpn Circ Soc 2012, 76:137-144.
15. Zhang B.-H., Guo C.-X., Wang H.-X., Lu L.-Q., Wang Y.-J., Zhang L.-K., et al. Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels 2013.
16. Simpkin J.C., Yellon D.M., Davidson S.M., Lim S.Y., Wynne A.M., Smith C.C.T. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 2007, 102:518-528.
17. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., et al. Characterization of apelin, the ligand for the APJ receptor. JNeurochem 2000, 74:34-41.
18. Szokodi I., Tavi P., Földes G., Voutilainen-Myllylä S., Ilves M., Tokola H., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002, 91:434-440.
19. El Messari S., Iturrioz X., Fassot C., De Mota N., Roesch D., Llorens-Cortes C. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. JNeurochem 2004, 90:1290-1301.
20. Kuba K., Zhang L., Imai Y., Arab S., Chen M., Maekawa Y., et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007, 101:e32-e42.
21. Ashley E.A., Powers J., Chen M., Kundu R., Finsterbach T., Caffarelli A., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading invivo. Cardiovasc Res 2005, 65:73-82.
22. Maguire J.J., Kleinz M.J., Pitkin S.L., Davenport A.P. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009, 54:598-604.
23. Wang W., McKinnie S.M.K., Patel V.B., Haddad G., Wang Z., Zhabyeyev P., et al. Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. JAm Heart Assoc 2013, 2:e000249.
24. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251:471-476.
25. Murza A., Belleville K., Longpré J.-M., Sarret P., Marsault E. Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid. Biopolymers 2014, 101:293-303.
26. Azizi Y., Faghihi M., Imani A., Roghani M., Nazari A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013, 46:76-82.
27. Brito L., Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomed 2007, 2:143-161.
28. Yuan A., Wu J., Song C., Tang X., Qiao Q., Zhao L., et al. Anovel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity. JPharm Sci 2013, 102:1626-1635.
29. Donaldson K., Duffin R., Langrish J.P., Miller M.R., Mills N.L., Poland C.A., et al. Nanoparticles and the cardiovascular system: a critical review. Nanomed 2013, 8:403-423.
30. Gunaseelan S., Gunaseelan K., Deshmukh M., Zhang X., Sinko P.J. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv Drug Deliv Rev 2010, 62:518-531.
31. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36-48.
32. Medina O.P., Zhu Y., Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004, 10:2981-2989.
33. Fleisher D., Niemiec S.M., Oh C.K., Hu Z., Ramachandran C., Weiner N. Topical delivery of growth hormone releasing peptide using liposomal systems: an invitro study using hairless mouse skin. Life Sci 1995, 57:1293-1297.
34. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
35. Kumar P., Gulbake A., Jain S.K. Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy. Crit Rev Ther Drug Carr Syst 2012, 29:355-419.
36. Lestini B.J., Sagnella S.M., Xu Z., Shive M.S., Richter N.J., Jayaseharan J., et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. JControl Release Off J Control Release Soc 2002, 78:235-247.
37. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-744.
38. Waterhouse D.N., Madden T.D., Cullis P.R., Bally M.B., Mayer L.D., Webb M.S. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol 2005, 391:40-57.
39. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta BBA - Biomembr 1993, 1151:201-215.
40. Xu H., Deng Y., Chen D., Hong W., Lu Y., Dong X. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. JControl Release Off J Control Release Soc 2008, 130:238-245.
41. Chen Z., Deng, Zhao, Tao Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake invitro and improved pharmacokinetics in rats. Int J Nanomed 2012, 3803.
42. El Maghraby G.M.M., Williams A.C., Barry B.W. Drug interaction and location in liposomes: correlation with polar surface areas. Int J Pharm 2005, 292:179-185.
43. Tamargo J., Duarte J., Caballero R., Delpón E. New therapeutic targets for the development of positive inotropic agents. Discov Med 2011, 12:381-392.
44. Andersen C.U., Hilberg O., Mellemkjaer S., Nielsen-Kudsk J.E., Simonsen U. Apelin and pulmonary hypertension. Pulm Circ 2011, 1:334-346.
45. Mesmin C., Renvoisé M., Becher F., Ezan E., Fenaille F. MS-based approaches to unravel the molecular complexity of proprotein-derived biomarkers and support their quantification: the examples of B-type natriuretic peptide and apelin peptides. Bioanalysis 2012, 4:2851-2863.
46. Japp A.G., Cruden N.L., Amer D.A.B., Li V.K.Y., Goudie E.B., Johnston N.R., et al. Vascular effects of apelin invivo in man. JAm Coll Cardiol 2008, 52:908-913.
47. Scimia M.C., Hurtado C., Ray S., Metzler S., Wei K., Wang J., et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012, 488:394-398.
48. Parasuraman S., Raveendran R., Kesavan R. Blood sample collection in small laboratory animals. JPharmacol Pharmacother 2010, 1:87-93.
49. Pitkin S.L., Maguire J.J., Kuc R.E., Davenport A.P. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010, 160:1785-1795.
50. Japp A.G., Cruden N.L., Barnes G., van Gemeren N., Mathews J., Adamson J., et al. Acute cardiovascular effects of apelin in humans potential role in patients with chronic heart failure. Circulation 2010, 121:1818-1827.
51. Katugampola S.D., Maguire J.J., Matthewson S.R., Davenport A.P. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001, 132:1255-1260.
52. Tasci I., Dogru T., Naharci I., Erdem G., Yilmaz M.I., Sonmez A., et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 2007, 115:428-432.
53. Leeper N.J., Tedesco M.M., Kojima Y., Schultz G.M., Kundu R.K., Ashley E.A., et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009, 296:H1329-H1335.
54. Kleinz M.J., Baxter G.F. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008, 146:271-277.
55. Mahmoudi M., Sant S., Wang B., Laurent S., Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011, 63:24-46.
56. Kumar A., Zhang X., Liang X.-J. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol Adv 2013, 31:593-606.
57. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008, 3:133-149.
58. Mahmoudi M., Lynch I., Ejtehadi M.R., Monopoli M.P., Bombelli F.B., Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem Rev 2011, 111:5610-5637.
59. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". JControl Release Off J Control Release Soc 2012, 161:164-174.
60. Jia Z.Q., Hou L., Leger A., Wu I., Kudej A.B., Stefano J., et al. Cardiovascular effects of a PEGylated apelin. Peptides 2012, 38:181-188.
61. Roberts M.J., Bentley M.D., Harris J.M. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002, 54:459-476.
62. Rezler E.M., Khan D.R., Tu R., Tirrell M., Fields G.B. Peptide-mediated targeting of liposomes to tumor cells. Methods Mol Biol Clifton N. J 2007, 386:269-298.
63. Rezler E.M., Khan D.R., Lauer-Fields J., Cudic M., Baronas-Lowell D., Fields G.B. Targeted drug delivery utilizing protein-like molecular architecture. JAm Chem Soc 2007, 129:4961-4972.
64. Chono S., Fukuchi R., Seki T., Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. JControl Release Off J Control Release Soc 2009, 137:104-109.
65. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
66. Lee H., Jang I.H., Ryu S.H., Park T.G. N-terminal site-specific mono-pegylation of epidermal growth factor. Pharm Res 2003, 20:818-825.
67. Visser C.C., Stevanović S., Voorwinden L.H., van Bloois L., Gaillard P.J., Danhof M., et al. Targeting liposomes with protein drugs to the blood-brain barrier invitro. Eur J Pharm Sci Off J Eur Fed Pharm Sci 2005, 25:299-305.
68. Xie Y., Ye L., Zhang X., Cui W., Lou J., Nagai T., et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: invitro and invivo studies. JControl Release Off J Control Release Soc 2005, 105:106-119.
69. Robinson S.N., Talmadge J.E. Sustained release of growth factors. Vivo Athens Greece 2002, 16:535-540.
70. Woodle M.C., Matthay K.K., Newman M.S., Hidayat J.E., Collins L.R., Redemann C., et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1992, 1105:193-200.
71. Kim A., Yun M.O., Oh Y.K., Ahn W.S., Kim C.K. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 1999, 180:75-81.
72. Choi K.Y., Yoon H.Y., Kim J.-H., Bae S.M., Park R.-W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5:8591-8599.
73. Fenske D.B., Palmer L.R., Chen T., Wong K.F., Cullis P.R. Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells. Biochim Biophys Acta 2001, 1512:259-272.
74. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. JControl Release Off J Control Release Soc 2011, 153:141-148.
75. Rosenson S. R. Myocardial injury: the acute phase response and lipoprotein metabolism. JAm Coll Cardiol 1993, 22:933-940.
76. Mackiewicz A., Kushner I., Baumann H. Acute phase proteins molecular biology, biochemistry, and clinical applications 1993, CRC Press.
77. Gruys E., Toussaint M.J.M., Niewold T.A., Koopmans S.J. Acute phase reaction and acute phase proteins. JZhejiang Univ Sci B 2005, 6:1045-1056.
78. Sanchez O., Arnau A., Pareja M., Poch E., Ramirez I., Soley M. Acute stress-induced tissue injury in mice: differences between emotional and social stress. Cell Stress Chaperones 2002, 7:36-46.
79. Cray C., Zaias J., Altman N.H. Acute phase response in animals: a review. Comp Med 2009, 59:517-526.
80. Monopoli M.P., Åberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012, 7:779-786.
81. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Baldelli Bombelli F., et al. Physical-chemical aspects of protein corona: relevance to invitro and invivo biological impacts of nanoparticles. JAm Chem Soc 2011, 133:2525-2534.
82. Hajipour M.J., Laurent S., Aghaie A., Rezaee F., Mahmoudi M. Personalized protein coronas: a "key" factor at the nanobiointerface. Biomater Sci 2014, 2:1210-1221.